ClinicalTrials.gg
CompletedNCT01517802Updated May 10, 2022Results posted

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

A Phase 3 interventional study of Abiraterone acetate and Prednisone in Metastatic Castration-resistant Prostate Cancer and Metastatic Breast Cancer, sponsored by Janssen Research & Development, LLC. Completed at 22 sites in 7 countries. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Breast Neoplasms by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Johnson & Johnson.

Enrollment
17th of 18
32 · median 114
Started
2012
the only one that year
Phase 3
7 of 19
none open now
Registered
14th of 19
by date

Among the 19 studies in Breast Neoplasms by Johnson & Johnson, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 3, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 19 studies in Breast Neoplasms by Johnson & Johnson is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.

Read the detailed description

This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or commercial source of abiraterone acetate) is available and feasible. Each cycle of treatment will be 28 days. Investigators will monitor and assess the patients for response to treatment or progression according to routine practice or as clinically indicated to determine whether continued treatment with abiraterone acetate is warranted. No efficacy data are being collected. Safety will be monitored throughout the study for a maximum duration of 9 years. End-of-study assessments will be performed at least 30 days after the last dose of abiraterone or upon early withdrawal.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic castration-resistant prostate cancer
  • Metastatic breast cancer
  • Abiraterone acetate
  • Low-dose corticosteroid treatment
  • Long-term access
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that require hospitalization.
  • Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate

    Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.

    Drug: Abiraterone acetate · Drug: Prednisone

Interventions

  • Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily

  • Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.

    Time frame: Up to 9 years

07

Results

Posted May 10, 2022
Limitations and caveats
No site qualification or initiation visits conducted for previous studies on abiraterone acetate. No formal case report forms were developed nor clinical database was generated to capture data in this study. Due to disease condition, most of participants were lost to follow-up and hence data collected was not as planned. Data were recorded based on available source notes at participating sites and thereby into CIOMS. Studied population was very small hence it was difficult to generalize results.

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone Acetate + Prednisone/Prednisolone
Started31
Completed30
Not completed1
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.

Time frame:
Up to 9 years
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsAbiraterone Acetate + Prednisone/Prednisolone
Number of Participants With Serious Adverse Events (SAEs)16

Adverse events

Collected over Up to 9 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate + Prednisone/Prednisolone1/31 (3.2%)16/31 (51.6%)0/31 (0%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAbiraterone Acetate + Prednisone/Prednisolone
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders3/31
DiarrhoeaGastrointestinal disorders2/31
FallInjury, poisoning and procedural complications2/31
Skin LacerationInjury, poisoning and procedural complications2/31
Lower Respiratory Tract InfectionInfections and infestations1/31
Urinary Tract InfectionInfections and infestations1/31
DehydrationMetabolism and nutrition disorders1/31
Cerebrovascular AccidentNervous system disorders1/31
EncephalopathyNervous system disorders1/31
Spinal Cord CompressionNervous system disorders1/31
Most frequent other events
Showing 10 of 27
Most frequent other events
EventAbiraterone Acetate + Prednisone/Prednisolone
Lower Respiratory Tract InfectionInfections and infestations0/31
Urinary Tract InfectionInfections and infestations0/31
DehydrationMetabolism and nutrition disorders0/31
Cerebrovascular AccidentNervous system disorders0/31
EncephalopathyNervous system disorders0/31
Spinal Cord CompressionNervous system disorders0/31
SyncopeNervous system disorders0/31
Cardiac FailureCardiac disorders0/31
Cardiac Failure CongestiveCardiac disorders0/31
Myocardial InfarctionCardiac disorders0/31

Baseline characteristics

Age, Customized
Age, Customized(Participants)Abiraterone Acetate + Prednisone/Prednisolone
63-90 years31
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate + Prednisone/Prednisolone
Female0
Male31
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Abiraterone Acetate + Prednisone/Prednisolone
08

Study locations

22 sites
  • Aurora, Colorado, United States
  • Marrero, Louisiana, United States
  • Boston, Massachusetts, United States
  • Omaha, Nebraska, United States
  • East Setauket, New York, United States
  • New York, New York, United States
  • Myrtle Beach, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Kogarah, Australia
  • Kurralta Park, Australia
  • South Brisbane, Australia
  • Subiaco, Australia
  • Antwerpen, Belgium
  • Hamburg, Germany
  • Barcelona, Spain
  • Uppsala, Sweden
  • Newcastle Upon Tyne, United Kingdom
  • Northwood, United Kingdom
  • Sutton, United Kingdom
  • Whitchurch, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Apr 2021, 108 months.

Results were first posted in May 2022, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 108 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2012
First posted
Jan 25, 2012
StartActual
Mar 28, 2012
Primary completionActual
Apr 22, 2021
CompletionActual
Apr 22, 2021
Results first posted
May 10, 2022
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01517802
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Mar 28, 2012
Primary completion
Apr 22, 2021
Completion
Apr 22, 2021
Results posted
May 10, 2022
Last update
May 10, 2022

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion